-
AASLD Voice of China | Dr. Hongfei Zhang’s Team: Latest Stage Data Revealed for China’s “Sprout” Project, Aiding Clinical Cure for Children with Chronic Hepatitis B
Editor’s Note: Chronic hepatitis B is the leading cause of liver disease in Chinese children, posing a serious threat to their health. The “Sprout” project is China’s first large-scale real-world…
-
AASLD Voice of China | Dr. Chao Wu and Dr. Jie Li’s Team at Nanjing Drum Tower Hospital Focus on Non-invasive Diagnosis
Risk Factors, and Treatment Management of Hepatitis, Yielding Fruitful Results! Editor’s Note: Hepatitis B virus (HBV) infection is a widespread global health issue. According to the World Health Organization, as…
-
New KRAS G12C Inhibitor Shows Early Efficacy in Solid Tumors and Previously Treated NSCLC
According to results from the phase 1a/1b LOXO-RAS-20001 study (NCT04956640) showcased at the 2023 American Association for Cancer Research (AACR) annual meeting, the KRAS G12C inhibitor LY3537982 exhibited clinical efficacy in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors. This is a phase I study of LY3537982 treating locally…
-
Emerging Lymphoma Therapies at AACR 2023: Promising Results in CD19 Immunotherapy, CAR-T Cells, and Dual-Specific Antibodies
The 2023 American Association for Cancer Research (AACR) Annual Meeting was held in Orlando, USA, from April 14 to 19, 2023. Every year, the AACR Congress reports numerous clinical, basic, and translational studies on cancer, especially innovative therapies in the preliminary phase I/II research stages. At this year’s AACR conference, three clinical trials were reported…
-
IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence
Recent findings from the phase III IMbrave050 trial presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting have unveiled a significant advancement in the treatment of hepatocellular carcinoma (HCC). The trial investigated the impact of adjuvant therapy with atezolizumab in combination with bevacizumab on recurrence-free survival (RFS) in HCC patients at high…
-
AASLD China Voice | Professor Wei Lai’s Team at Tsinghua Chang Gung: Latest Developments in the Nationwide “MAFLD Epidemiological Survey Research Pro
AASLD China Voice | Professor Wei Lai’s Team at Tsinghua Chang Gung: Latest Developments in the Nationwide “MAFLD Epidemiological Survey Research Project” on Health Check-up Populations Editor’s Note: In 2020,…
-
KEYNOTE-966 Study Published in “The Lancet”: Pembrolizumab Combined with Chemotherapy Brings Significant Survival Benefits to Advanced Biliary Tract
According to the KEYNOTE-966 study results announced at the 2023 American Association for Cancer Research (AACR) annual meeting, adding pembrolizumab on the basis of gemcitabine and cisplatin brings statistically and clinically significant survival benefits to patients with advanced biliary tract cancer. These results validate the outcomes of the randomized phase III TOPAZ-1 study. Encouragingly, this…
-
AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released
According to the preliminary results of the phase III AEGEAN trial (NCT03800134) interim analysis presented at the AACR Annual Meeting in 2023, in patients with resectable non-small cell lung cancer (NSCLC), the perioperative durvalumab combined with platinum-based neoadjuvant chemotherapy showed statistically significant improvements in pathological complete response (pCR) and event-free survival (EFS) compared to placebo…
Connecting Medical Expertise through Media